Table 3.
Clinicopathological characteristics of RECI2 patients (N = 14)
| Patient | Gender | Progression-free interval, mo | OS, mo | % of SEMA6A+ cells | SEMA6A IS | Tumor site |
|---|---|---|---|---|---|---|
| Short-Term Responders | ||||||
| 1 | F | 12 | 35 | 70% | 2 | Metastasis |
| 4 | M | 9 | 16 | 60% | 2 | Lung |
| 10 | F | 11 | 18 | 60% | 2 | Lymph node |
| 50% | 1 | Lung | ||||
| 13 | F | 4 | 20 | 60% | 2 | Lung and lymph node |
| 14 | F | 8 | 98 | 70% | 2 | Occipital fragment |
| 15 | F | 12 | 27 | 50% | 1 | Lung |
| Long-Term Responders | ||||||
| 2 | M |
Ongoing 67 |
68 | 30% | 1 | Middle meatus |
| 3 | F |
Ongoing 58 |
91 | 30% | 1 | Lymph node |
| 5 | M | 39 | 63 | 60% | 2 | Back |
| 6 | M | 24 | 50 | 30% | 1 | Lung |
| 7 | M | 60 | 75 | 30% | 2 | Face |
| 8 | M |
Ongoing 82 |
83 | 30% | 2 | Back |
| 9 | M | 48 | 86 | 30% | 2 | Lung |
| 11 | F |
Ongoing 75 |
80 | 30% | 1 | Lymph node |